Amedisys (NASDAQ:AMED) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
AMED has been the subject of a number of other reports. Jefferies Group set a $70.00 price target on Amedisys and gave the company a “buy” rating in a research note on Wednesday, February 28th. Oppenheimer increased their price target on Amedisys from $68.00 to $63.00 and gave the company an “outperform” rating in a research note on Thursday, March 1st. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Tuesday, March 6th. TheStreet lowered Amedisys from a “b” rating to a “c+” rating in a research note on Wednesday, February 28th. Finally, William Blair reissued an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $63.18.
Amedisys (NASDAQ AMED) opened at $62.73 on Thursday. Amedisys has a one year low of $45.60 and a one year high of $65.91. The company has a market capitalization of $2,085.99, a P/E ratio of 71.28, a P/E/G ratio of 1.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.45 and a current ratio of 1.45.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, February 27th. The health services provider reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Amedisys had a net margin of 1.98% and a return on equity of 15.14%. The firm had revenue of $404.24 million for the quarter, compared to the consensus estimate of $394.96 million. During the same period in the previous year, the company posted $0.44 earnings per share. equities analysts anticipate that Amedisys will post 3 EPS for the current year.
Hedge funds have recently modified their holdings of the business. Systematic Financial Management LP raised its holdings in shares of Amedisys by 3.3% in the fourth quarter. Systematic Financial Management LP now owns 29,850 shares of the health services provider’s stock worth $1,573,000 after buying an additional 945 shares during the period. Teachers Advisors LLC raised its holdings in shares of Amedisys by 1.5% in the fourth quarter. Teachers Advisors LLC now owns 80,867 shares of the health services provider’s stock worth $4,262,000 after buying an additional 1,191 shares during the period. American International Group Inc. raised its holdings in shares of Amedisys by 6.0% in the third quarter. American International Group Inc. now owns 22,560 shares of the health services provider’s stock worth $1,262,000 after buying an additional 1,285 shares during the period. Swiss National Bank raised its holdings in shares of Amedisys by 3.2% in the fourth quarter. Swiss National Bank now owns 49,000 shares of the health services provider’s stock worth $2,583,000 after buying an additional 1,500 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Amedisys by 3.3% in the third quarter. Rhumbline Advisers now owns 55,951 shares of the health services provider’s stock worth $3,131,000 after buying an additional 1,765 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/17/amedisys-amed-rating-increased-to-buy-at-bidaskclub.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.